Go to the profile of Teva Pharmaceuticals

Teva Pharmaceuticals

 
  • +1 610 727 3222 or +1-610-786-7158
  • Leaders
  • United States of America
Go to the profile of Nanda Kumar
Nanda Kumar

Research on Host cell Interaction - Mass Spectrometry at Ernst Moritz Arndt - Universitat Greifswald, Ernst Moritz Arndt - Universitat Greifswald

Go to the profile of Ericka Moore
Ericka Moore

Director of Sales , SOLABS

SOLABS QM is an integrated EQMS Software that helps Medical Device, Pharmaceutical, Biotechnology, Clinical Trials, and Research & Development companies improve their operational efficiency and audit response times, and maintain GxP, GCP & GMP compliance by automating Quality Operations with respect to FDA 21 CFR Part 11 and Annex 11.
At MyCartis, people strongly believe in bringing personalized diagnostics to healthcare. To achieve such ambitious goal, disruptive technologies allowing the measurement of syndromic biomarker panels are needed. MyCartis offers such new microfluidic biomarker analysis platform called Evalution, combining exclusive features to serve the research as well as the clinical market. Encoded microparticles layered in a 16-channel microfluidic cartridge form the basis of multiplex assays with demonstrated superior technical and analytical specifications. MyCartis will work with selected partners to bring an exciting biomarker assay portfolio to both the life science and IVD end-user. The Evalution technology now provides researchers the opportunity to easily build custom multiplex assays to study their biomarkers and diagnostic companies to commercialize them on a platform that integrates pre-analytical and detection workflows, all without the need to ever change platform: one technology, from basic biomarker research until IVD application.
Go to the profile of Debayan Bose
Debayan Bose

Student, Academia Sinica

Go to the profile of Erick Ngosia
Erick Ngosia

CEO, Farick Ltd

Go to the profile of Yuko Takai
Yuko Takai

Sales Manager, Nature Publishing Group

Two research collaborations, one with the synthetic biochemistry team at GlaxoSmithKline (GSK) and the other with the Centre for Synthetic Biology and the department of bioengineering at Imperial College, London, have Sphere Fluidics working at the cutting edge of mass spectrometry (MS) and synthetic biology. MS is the technique of choice for characterizing proteins and chemicals and for distinguishing nuances between metabolite concentrations in biological samples. Following atom ionization, the masses of the molecules and their derivatives can be determined. However, compared to other technologies used to characterize biological samples such as genome sequencing, MS is a lowthroughput process. Sphere Fluidics’ picodroplet technology now provides a high-throughput approach for analyzing single cells or a few hundred picoliters of fluid containing the molecules of interest. The technology platform is already used to support a number of applications in the academic and biopharmaceutical research communities.
Go to the profile of Veronica Zacatenco
Veronica Zacatenco

Business Development Executive, Nature Publishing Group

Our team makes every effort to support the business development needs of the biopartnering community through our publications BioPharma Dealmakers, MedTech Dealmakers and our series of associated webcasts. I am interested in hearing about your partnering communication needs as well as your suggestions or comments.
Go to the profile of Raveena Bhambra
Raveena Bhambra

Editor, BioPharma Dealmakers , Nature Research

Hello all, I am the Editor of BioPharma Dealmakers, a quarterly publication that assists companies in identifying potential partners in the pharmaceutical and biotechnology industry and appears in both Nature Biotechnology and Nature Reviews Drug Discovery. I am very passionate about the biopharma industry and have over 15 years of experience of working in the field, specifically in dealmaking, partnering and licensing. In my previous roles I have conducted partner searches identifying both products/technologies and partners for clients, and have edited and written dealmaking-focused reports.
Go to the profile of Jen Thoroughgood
Jen Thoroughgood

Former Head of Communities, Springer Nature

I'm no longer with Springer Nature so please send your community-related queries to communities@nature.com. Thanks!
Go to the profile of Jenefer Thoroughgood
Jenefer Thoroughgood

Managing Director, Thoroughly Good Consulting

For nearly 20 years, I've worked in the digital media sector, with hands-on experience in editorial, marketing, sales and R&D. I'm passionate about engaging and understanding customers to develop great content and products. Formerly Chief Product & Customer Officer at Zapnito, I'm now an advisor to the company.
Go to the profile of Matt Kay
Matt Kay

Product Manager, Nature Publishing Group

Go to the profile of Claire Thompson
Claire Thompson

Global Manager, Business Development, Nature Publishing Group

I head up the business development team responsible for Nature's special partnering publications, BioPharma Dealmakers and MedTech Dealmakers, plus our series of associated webcasts. The team and I take a highly consultative approach to ensure that the individual business development needs of all the companies we with work, from the largest to the smallest, are effectively supported. I welcome the opportunity to hear from you, whether to investigate how our special partnering publications and tools might support your company, or to hear about your comments and suggestions.
Go to the profile of Charles Thiede
Charles Thiede

CEO & Co-Founder, Zapnito

My background is in technology, professional services and digital media. I co-founded Zapnito due to a number of related observations from my time in these sectors: 1) the social web is creating a huge amount of noise 2) expertise that brands have built up over decades is being drowned out and hidden from those that need it 3) these brands are therefore losing their audience to often undeserving and unhelpful sources, and 4) people are finding it harder to access the expertise that they truly value. I therefore decided to create Zapnito, a white-label platform to help trusted brands reclaim their audiences via expert-driven knowledge networks.
Go to the profile of Jon Beer
Jon Beer

CTO, Zapnito

A technical leader and hands-on CTO with 17 years' experience implementing web technologies. I lead the technical delivery of the Zapnito platform, ensuring a scalable multi-tenant architecture, disruption-free daily release cycles and a highly effective development team that delivers platform enhancements for our customers. Get in touch with me to discuss your requirements for this or any Zapnito network or to share your feedback at any time.